SHANGHAI MICURX PHARMACEUTICAL CO., LTD. competitors & alternatives

AicurisPharmaGermany

70% match

Pharma

AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.

QureTech BioBiotechnology, Drug DiscoverySweden

68% match

Biotechnology, Drug Discovery

QureTech Bio is a biotechnology company that develops treatments to defeat bacterial virulence and restore antibiotic susceptibility, specifically targeting drug-resistant infections such as Staphylococcus aureus. The company serves the pharmaceutical and healthcare sectors by advancing novel antibacterial portfolios and seeking partnership opportunities.

Protez PharmaceuticalsPharmaceuticalsUnited States

67% match

Similar pharmaceuticals company

Protez Pharmaceuticals is a pharmaceutical and medical research company founded in 2003 and focused on the discovery and development of novel injectable and oral small molecule antibiotics for hospital-based, difficult-to-treat infections. The company was acquired by Novartis AG in June 2008.

Similar pharmaceuticals company

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

Paratek PharmaceuticalsPharmaceuticalsUnited States

66% match

Similar pharmaceuticals company

Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.

CureGene PharmaceuticalPharmaceuticalsChina

65% match

Similar pharmaceuticals company

Shanghai CureGene Pharmaceutical Co., Ltd. is a biopharmaceutical company founded in Zhangjiang, Shanghai, in 2018. It specializes in developing state-of-the-art medications and has built a globally leading targeted prodrug platform.

Similar pharmaceuticals company

Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.

RECREO PHARMACEUTICALS LLCPharmaceuticalsUnited States

65% matchPrivate

Similar pharmaceuticals company

Recreo Pharmaceuticals LLC is a healthcare company focused on developing and testing antibiotics to combat antibiotic resistance and improve patient health. The firm monitors industry trends and medical technology to advance its drug development initiatives.

Similar pharmaceuticals company

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company based in Oklahoma City, Oklahoma, developing orally active compounds that restore the efficacy of existing antibiotics.

Guangzhou Sanofi Pasteur Co., Ltd.Pharmaceuticals (Vaccines)China

64% match

Pharmaceuticals (Vaccines)

Guangzhou Sanofi Pasteur Co., Ltd. is a research-driven biopharmaceutical company that develops and provides a portfolio of high-quality medicines and vaccines. The company serves patients and healthcare needs by leveraging scientific research and innovation within the Chinese market.

Venatorx PharmaceuticalsPharmaceuticalsUnited States

64% match

Similar pharmaceuticals company

Venatorx Pharmaceuticals, Inc. is a pharmaceutical manufacturing company based in Malvern, Pennsylvania, focused on the discovery and development of novel anti-infective treatments.

BAO PHARMA-B02659 · PharmaceuticalsChina

64% matchPublic

Similar pharmaceuticals company

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium–sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.